Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Leukemia Patients
100%
Plasma Fibrinogen
85%
MELD Score
85%
Decompensated Cirrhosis
85%
Diffuse Large B-cell Lymphoma (DLBCL)
85%
Disease Score
85%
Fibrinogen
68%
Chemotherapy
57%
Non-Hodgkin Lymphoma
53%
Chronic Myeloid Leukemia
42%
Imatinib Therapy
42%
Acute Myeloid Leukemia Cells
42%
Difference Expression
42%
Therapy Response
42%
Progressive multifocal Leukoencephalopathy
42%
John Cunningham Virus
42%
R-CHOP Chemotherapy
42%
Chronic Lymphocytic Leukemia
42%
Disseminated Histoplasmosis
42%
Cytarabine
42%
Estimated Glomerular Filtration Rate
42%
Cell Culture
42%
CD34+
42%
Splenomegaly
42%
Pancytopenia
42%
Lymphoma Patients
42%
Age-matched
42%
MicroRNA-21 (miR-21)
42%
Treatment Duration
42%
Neutrophil-to-lymphocyte Ratio
42%
Plasma miRNAs
42%
Acute Myeloid Leukemia
35%
General Hospital
27%
Chronic Hematological Malignancies
24%
Surabaya
24%
Doxorubicin
21%
Peripheral Blood Mononuclear Cells
21%
Chemotherapy Regimen
21%
Response to Chemotherapy
21%
Anemia
21%
Oncovin
21%
Rituximab
21%
Cyclophosphamide
21%
Prednisone
21%
Coagulation Disorders
17%
Hepatitis C
17%
Sysmex
17%
Virus-induced
17%
Hepatitis B
17%
Score Level
17%
Pharmacology, Toxicology and Pharmaceutical Science
End Stage Liver Disease
85%
Decompensated Liver Cirrhosis
85%
Fibrinogen
85%
Chemotherapy Regimens
57%
Imatinib
42%
Chronic Myeloid Leukemia
42%
Diffuse Large B Cell Lymphoma
42%
Chronic Lymphatic Leukemia
42%
JC Virus
42%
Progressive Multifocal Leukoencephalopathy
42%
Acute Myeloid Leukemia
42%
Cytarabine
42%
Daunorubicin
42%
Cell Culture
42%
Pancytopenia
42%
Histoplasmosis
42%
Nonhodgkin Lymphoma
21%
Side Effect
21%
Diseases
17%
Ajellomyces capsulatus
14%
Observational Study
12%
Blood Clotting Factor
12%
Blood Clotting Disorder
12%
Bleeding
12%
Hepatitis C
12%
Hepatitis B
12%
Cross-Sectional Study
12%
Vincristine
10%
Prednisone
10%
Cyclophosphamide
10%
Vincristine Sulfate
10%
Rituximab
10%
Doxorubicin
10%
Anemia
10%
Hematologic Malignancy
8%
Mefloquine
8%
Virus Infection
8%
Ethylenediaminetetraacetic Acid
7%
Remission
7%
Carbon Dioxide
7%
Treatment Group
7%
Bone Marrow Suppression
5%
Prevalence
5%
Primary Tumor
5%
Leukopenia
5%
Medicine and Dentistry
Chemotherapy
50%
Cell Culture
42%
Histoplasmosis
42%
Imatinib
42%
Chronic Myelogenous Leukemia
42%
Lymphoma Cell
42%
Acute Myeloid Leukemia
42%
Leukemia Cell
42%
Cytarabine
42%
Liposomal Daunorubicin
42%
Splenomegaly
42%
Treatment Response
42%
Pancytopenia
42%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
42%
Lymphocyte
42%
Neutrophil
42%
Peripheral Blood Mononuclear Cell
21%
Diffuse Large B-Cell Lymphoma
16%
Prevalence
14%
Hemophagocytic Syndrome
14%
Bone Marrow Examination
14%
Chemosensitivity
14%
Itraconazole
14%
Mycosis
14%
Human Immunodeficiency Virus Infection
14%
Immune Deficiency
14%
Immunosuppressive Drug
14%
Non-Hodgkin Lymphoma
10%
Neoplasm
10%
Observational Study
7%
Treatment Group
7%
Quantitative Reverse Transcription Polymerase Chain Reaction
7%
Intermediate Risk Population
7%
Low Risk Population
7%
In Vitro
7%
Carbon Dioxide
7%
Induction Chemotherapy
7%
Edetic Acid
7%
High Risk Population
7%
Spontaneous Remission
7%
Diseases
5%
Medical Record
5%
Progressive Disease
5%
Immunosuppressive Treatment
5%
Angiogenesis
5%